ATE260679T1 - Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid - Google Patents

Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid

Info

Publication number
ATE260679T1
ATE260679T1 AT93909508T AT93909508T ATE260679T1 AT E260679 T1 ATE260679 T1 AT E260679T1 AT 93909508 T AT93909508 T AT 93909508T AT 93909508 T AT93909508 T AT 93909508T AT E260679 T1 ATE260679 T1 AT E260679T1
Authority
AT
Austria
Prior art keywords
components
self
delivery system
polynucleotide
organizing
Prior art date
Application number
AT93909508T
Other languages
English (en)
Inventor
Francis C Szoka Jr
Jean Haensler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27127858&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE260679(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE260679T1 publication Critical patent/ATE260679T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2261/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G2261/30—Monomer units or repeat units incorporating structural elements in the main chain
    • C08G2261/31—Monomer units or repeat units incorporating structural elements in the main chain incorporating aromatic structural elements in the main chain
    • C08G2261/312—Non-condensed aromatic systems, e.g. benzene

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT93909508T 1992-04-03 1993-04-05 Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid ATE260679T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86487692A 1992-04-03 1992-04-03
US91366992A 1992-07-14 1992-07-14
PCT/US1993/003406 WO1993019768A1 (en) 1992-04-03 1993-04-05 Self-assembling polynucleotide delivery system

Publications (1)

Publication Number Publication Date
ATE260679T1 true ATE260679T1 (de) 2004-03-15

Family

ID=27127858

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909508T ATE260679T1 (de) 1992-04-03 1993-04-05 Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid

Country Status (11)

Country Link
US (3) US6300317B1 (de)
EP (2) EP1236473A3 (de)
JP (4) JP4074658B2 (de)
AT (1) ATE260679T1 (de)
AU (1) AU682308C (de)
CA (1) CA2133323C (de)
DE (1) DE69333434T2 (de)
DK (1) DK0636028T3 (de)
ES (1) ES2221920T3 (de)
PT (1) PT636028E (de)
WO (1) WO1993019768A1 (de)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
ES2211882T3 (es) * 1993-07-14 2004-07-16 The Regents Of The University Of California Sistema de cesion de polinucleotido, automontable que comprende policationes de dendrimeros.
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
WO1995034647A1 (en) * 1994-06-13 1995-12-21 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US6630455B1 (en) 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
JP3961019B2 (ja) 1995-02-28 2007-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子転移媒介の血管形成療法
WO1996030386A1 (fr) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
EP2168973A1 (de) * 1995-05-04 2010-03-31 Gilead Sciences, Inc. Komplexe von Nucleinsäureligand
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
JP2002514892A (ja) * 1995-06-08 2002-05-21 コブラ セラピューティクス リミテッド 遺伝子治療における合成ウイルス様粒子の使用
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US7026116B1 (en) 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US6444806B1 (en) * 1996-04-30 2002-09-03 Hisamitsu Pharmaceutical Co., Inc. Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
GB9623051D0 (en) * 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
CA2271325A1 (en) * 1996-11-12 1998-05-22 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
HU226662B1 (en) 1996-11-15 2009-06-29 Canji Nucleic acids coding for ezf-rb fusion polypeptides and expression vectors containing the same
FR2755976B1 (fr) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
US6074850A (en) * 1996-11-15 2000-06-13 Canji, Inc. Retinoblastoma fusion polypeptides
US6514987B1 (en) * 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US5948878A (en) * 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
WO1999005300A2 (en) 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
AUPP373698A0 (en) * 1998-05-27 1998-06-18 Commonwealth Scientific And Industrial Research Organisation Molecular coatings
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
DE69931166T2 (de) 1998-08-14 2007-02-15 Valentis Inc., Burlingame Co-lyophilisierter komplex umfassend einen nukleinsäurevektor und ein formulierungsagens
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1105490A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
FR2785293B1 (fr) 1998-10-30 2002-07-05 Pasteur Merieux Serums Vacc Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
EP1829856A3 (de) 1998-11-12 2009-02-25 Invitrogen Corporation Transfektionsreagenzien
US6277489B1 (en) * 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
IL143983A0 (en) 1999-01-08 2002-04-21 Amaxa Gmbh Use of cellular transport systems for the transfer of nucleic acids through the nuclear envelope
EP1046394A3 (de) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Neue Zusammensetzungen zur Verwendung bei der Verabreichung von Verbindungen in das Zellinnere
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US20080281041A1 (en) * 1999-06-07 2008-11-13 Rozema David B Reversibly Masked Polymers
US8541548B2 (en) * 1999-06-07 2013-09-24 Arrowhead Madison Inc. Compounds and methods for reversible modification of biologically active molecules
WO2001023537A1 (en) * 1999-09-24 2001-04-05 Cyto Pulse Sciences, Inc. Process for enhancing electric field-mediated delivery of biological materials into cells
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
AU2460001A (en) 1999-12-27 2001-07-09 Regents Of The University Of California, The Gene therapy for congestive heart failure
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
DE10016881B4 (de) * 2000-04-05 2006-06-01 Qiagen Gmbh Gezielte Transfektion von Zellen mittels biotinyliertem Dendrimer
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2825364A1 (fr) * 2001-05-29 2002-12-06 Genethon Iii Vecteur peptiidique pour le transfert d'acides nucleiques dans des cellules eucaryotes
CA2464199C (en) 2001-10-26 2013-12-24 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
MXPA04005713A (es) 2001-12-11 2005-06-06 Baylor College Medicine Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos.
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US8008355B2 (en) * 2002-03-11 2011-08-30 Roche Madison Inc. Endosomolytic poly(vinyl ether) polymers
US8138383B2 (en) * 2002-03-11 2012-03-20 Arrowhead Madison Inc. Membrane active heteropolymers
EP1356820A1 (de) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA-Impfstoff kombiniert mit einen Apoptoneauslöser von Tumorzellen
GB0228525D0 (en) * 2002-12-06 2003-01-15 Univ Cambridge Tech Polymers and their use
US7695752B2 (en) * 2003-01-24 2010-04-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
US7709047B2 (en) * 2003-01-24 2010-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
CA2557737C (en) 2003-03-12 2014-08-05 Advisys, Inc. Insulin-like growth factor (igf-i) plasmid-mediated supplementation for therapeutic applications
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
WO2005054438A2 (en) 2003-12-01 2005-06-16 Invitrogen Corporation Nucleic acid molecules containing recombination sites and methods of using the same
ATE551432T1 (de) 2004-06-21 2012-04-15 Univ Leland Stanford Junior Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
JPWO2006030788A1 (ja) * 2004-09-14 2008-05-15 信一郎 礒部 インターカレータ及びそれを用いた遺伝子検出方法
KR101504622B1 (ko) 2005-04-29 2015-03-20 에이전시 포 사이언스, 테크놀로지 앤드 리서치 고차가지구조 고분자 및 그들의 응용
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) * 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7957466B2 (en) * 2005-09-16 2011-06-07 Sony Corporation Adaptive area of influence filter for moving object boundaries
EP2564864B8 (de) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University Verfahren im Zusammenhang mit FGF2 zur Diagnose und Behandlung von Depressionen
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
WO2008022309A2 (en) * 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
US8017109B2 (en) * 2006-08-18 2011-09-13 Roche Madison Inc. Endosomolytic poly(acrylate) polymers
JP2010503414A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 正に荷電した部分を含有するポリマー複合体
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
CN102439150A (zh) 2009-03-27 2012-05-02 法国国家健康医学研究院 用于癌症治疗的卡那霉素反义核酸
GB0918679D0 (en) 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
GB0918782D0 (en) 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
JP5457813B2 (ja) * 2009-12-16 2014-04-02 ルネサスエレクトロニクス株式会社 Ａｄｐｌｌ回路、半導体装置及び携帯情報機器
GB201002413D0 (en) * 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
WO2011101031A1 (en) 2010-02-19 2011-08-25 Université de Liège A polynucleotide for use in treatment of influenza a virus induced diseases, encoding modified mx protein, said modified mx protein, and a transgenic animal expressing gene encoding modified mx protein
DK2539451T3 (da) 2010-02-24 2016-04-04 Arrowhead Res Corp Sammensætninger til målrettet tilførsel af siRNA
GB201004475D0 (en) 2010-03-17 2010-05-05 Isis Innovation Gene silencing
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012013249A1 (en) 2010-07-30 2012-02-02 Université de Liège Dentin matrix protein 1 (dmp1) for use in pharmaceutical compositions
GB201014026D0 (en) 2010-08-20 2010-10-06 Ucl Business Plc Treatment
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EP2776013B8 (de) * 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Verfahren und zusammensetzungen zur röntgeninduzierten freisetzung ph-empfindlicher liposome
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104271772A (zh) 2012-03-29 2015-01-07 科罗拉多州立大学董事会,公司实体 点击核酸
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014195713A1 (en) 2013-06-06 2014-12-11 David J Rowlands Single domain antibody display
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
WO2017156630A1 (en) * 2016-03-15 2017-09-21 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sante Et Humaines, S.E.C. Conjugates enhancing total cellular accumulation
EP3538546A1 (de) 2016-11-14 2019-09-18 Novartis AG Zusammensetzungen, verfahren und therapeutische verwendungen im zusammenhang mit fusogenem protein minion
WO2019112965A1 (en) * 2017-12-04 2019-06-13 The Regents Of The University Of California Compositions and methods for delivery of macromolecules
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (de) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Behandlung von krebs mit tumorinfiltrierenden lymphozyten
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
EP4337770A1 (de) 2021-05-13 2024-03-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur behandlung von sichelzellkrankheiten
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
AR127482A1 (es) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023087103A1 (en) 2021-11-16 2023-05-25 Defence Therapeutics Inc. Steroid acid-peptide based cytotoxic compounds
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4650909A (en) * 1984-11-28 1987-03-17 Yoakum George H Polyethylene glycol (PEG) reagent
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0428635A4 (en) * 1989-02-24 1993-03-10 City Of Hope Heterologous block oligomers
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991007947A1 (en) * 1989-12-05 1991-06-13 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE59106279D1 (de) * 1990-05-18 1995-09-21 Genentech Inc Neue protein-polykation-konjugate.
JPH06510278A (ja) * 1991-06-05 1994-11-17 ユニバーシティ オブ コネチカット 分泌タンパク質をコードする遺伝子の標的への配達
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
ES2104518T1 (es) * 1994-03-07 1997-10-16 Dow Chemical Co Conjugados dendrimeros bioactivos y/o directores hacia diana.

Also Published As

Publication number Publication date
DK0636028T3 (da) 2004-07-12
JP4074658B2 (ja) 2008-04-09
DE69333434T2 (de) 2005-03-03
AU682308B2 (en) 1997-10-02
EP0636028A4 (de) 1998-12-09
JPH07505639A (ja) 1995-06-22
EP0636028B1 (de) 2004-03-03
PT636028E (pt) 2004-07-30
JP2004000245A (ja) 2004-01-08
EP1236473A3 (de) 2003-01-15
JP2007006899A (ja) 2007-01-18
JP3950472B2 (ja) 2007-08-01
JP2005110696A (ja) 2005-04-28
AU682308C (en) 2006-08-17
JP3688278B2 (ja) 2005-08-24
US5977084A (en) 1999-11-02
WO1993019768A1 (en) 1993-10-14
US6300317B1 (en) 2001-10-09
ES2221920T3 (es) 2005-01-16
DE69333434D1 (de) 2004-04-08
CA2133323A1 (en) 1993-10-14
AU4027893A (en) 1993-11-08
EP0636028A1 (de) 1995-02-01
US5955365A (en) 1999-09-21
EP1236473A2 (de) 2002-09-04
CA2133323C (en) 2010-10-26
JP3907662B2 (ja) 2007-04-18

Similar Documents

Publication Publication Date Title
ATE260679T1 (de) Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
ATE258434T1 (de) Sich selbst zusammensetzendes polynukleotid- abgabesystem, das dendrimer-polykationen enthält
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE68909691D1 (de) Multischichtkörper zur Abgabe von Duftstoffen.
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DE69731710D1 (de) Lokalisierung von Schablonen in optischen Zeichenerkennungsanlagen
ATE417925T1 (de) Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE59401407D1 (de) Behälter zur aufnahme von gegenständen
ATE110743T1 (de) Antikoagulierende peptide.
DE69103699D1 (de) Kasten zur Aufnahme von Flaschen.
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
BR9815341A (pt) Sistema de ventilação de telhado, e, cumeeira de telhado para estufa.
DE69715181D1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE58900146D1 (de) Luftausstroemorgan fuer den innenraum von kraftfahrzeugen.
DE59301001D1 (de) Vorrichtung zur Sicherung von Ladegut.
DE69534738D1 (de) Leukocyten-aktivierender Faktor
DE59814002D1 (de) Sekretion von tragergebundenen proteinen in das periplasma und in den extrazellulären raum
DE69232771D1 (de) Peptide als antagonisten von endothelin
DE3888988D1 (de) Faltbares Spritzgestänge zur Zerstäubung von Chemikalien auf Getreidefeldern.
DE60036638D1 (de) Verwendung von colostrinin, dessen peptidbestandteile und deren analoga zur förderung der neuronalen zelldifferenzierung
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
ATE412175T1 (de) Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz
DE3784894D1 (de) Einrichtung zur anfuhr von schuettfaehigen sprengstoffen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0636028

Country of ref document: EP